This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis

This study has been completed.
Sponsor:
Collaborators:
The Hospital for Sick Children
Canadian Cystic Fibrosis Foundation
The Physicians' Services Incorporated Foundation
Information provided by (Responsible Party):
Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier:
NCT00528190
First received: September 10, 2007
Last updated: April 3, 2017
Last verified: February 2017
September 10, 2007
April 3, 2017
October 2007
August 2010   (Final data collection date for primary outcome measure)
The Primary Outcome Measure Will be the Number of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over the 24 Week Trial Treatment Period. [ Time Frame: 24 weeks ]
The Primary outcome measure will be the number of patients who experience a respiratory exacerbation requiring intravenous antibiotics in the two treatment groups over the 24 week trial treatment period.
The Primary Outcome Measure Will be the Proportion of Patients Who Experience a Respiratory Exacerbation Requiring Intravenous Antibiotics in the Two Treatment Groups Over the 24 Week Trial Treatment Period.
Complete list of historical versions of study NCT00528190 on ClinicalTrials.gov Archive Site
Not Provided
Respiratory Exacerbation Requiring Intravenous or Oral Antibiotics Over the 24 Week Trial Treatment Period. 2) Absolute and Relative Changes in the Force
Not Provided
Not Provided
 
Treatment of Aspergillus Fumigatus (a Fungal Infection) in Patients With Cystic Fibrosis
Treatment of Aspergillus Fumigatus in Patients With Cystic Fibrosis: A Randomized, Double-blind, Placebo-Controlled Trial
This clinical trial will attempt to determine whether we can improve clinical outcomes for patients with cystic fibrosis who are infected with a fungus called Aspergillus fumigatus.
The aim of this study is to determine whether antibiotic treatment directed against Aspergillus Fumigatus will be effective at preventing respiratory exacerbations and improving pulmonary function in patients with cystic fibrosis(CF) who are chronically colonized/infected with aspergillus. This aim will be accompanied by means of a randomized, double-blind, placebo-controlled clinical trial incorporating two parallel treatment arms.
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Prevention
Cystic Fibrosis
Drug: Itraconazole
Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
Other Name: non applicable
  • Experimental: Itraconazole
    Itraconazole 5mg/kg/day for 24 weeks
    Intervention: Drug: Itraconazole
  • Placebo Comparator: Placebo
    Placebo/day for 24 weeks
    Intervention: Drug: Itraconazole
Aaron SD, Vandemheen KL, Freitag A, Pedder L, Cameron W, Lavoie A, Paterson N, Wilcox P, Rabin H, Tullis E, Morrison N, Ratjen F. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One. 2012;7(4):e36077. doi: 10.1371/journal.pone.0036077. Epub 2012 Apr 30.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
May 2011
August 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria

  • Diagnosis of CF as defined by two or more clinical features of CF and a documented sweat chloride greater than 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations
  • Patient must be known to be chronically colonized with Aspergillus fumigatus.
  • Patients must be clinically stable at randomization, no use of new inhaled, oral or intravenous antibiotics or oral or intravenous corticosteroids during the 14-day period prior to randomization.
  • 6 years of age and older
  • Patients must weigh at least 20 kg
  • Post-menarche females must be using an effective form of contraception.

Exclusion Criteria

  • Inability to give informed consent.
  • Respiratory culture positive for B.cepacia complex
  • Renal function abnormalities-Creatinine greater than 1.5 times upper limit of normal within a 30 day period prior to randomization
  • Liver function abnormalities : AST or ALT greater or equal to 2.5 times the upper limit of normal within a 30 day period prior to randomization
  • Neutropenia, absolute neutrophil count< or = 1000 within a 3-day period prior to randomization
  • History of biliary cirrhosis documented by liver biopsy or imaging.
  • History of portal hypertension.
  • Investigational drug use within 30 days of randomization date.
  • History of alcohol, illicit drug or medication abuse within 1 year of randomization.
  • Women who are pregnant, breastfeeding or trying to conceive
Sexes Eligible for Study: All
6 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00528190
2006768
Yes
Not Provided
No
Not Provided
Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
  • The Hospital for Sick Children
  • Canadian Cystic Fibrosis Foundation
  • The Physicians' Services Incorporated Foundation
Principal Investigator: Shawn Aaron, MD OHRI
Ottawa Hospital Research Institute
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP